[Full Table of Contents]
[Executive Summary]

[Appendices] PDF version

  1. Acknowledgement of contributors
  2. Glossary
  3. Assumptions behind current burden, coverage and funding estimates
  4. Assumptions behind country implementation cost estimates
  5. Assumptions behind R&D cost estimates
  6. Compilation of WHO References


Appendix 3: Assumptions behind Current Burden, Coverage and Funding Estimates

Appendix 3 explains the data sources and methodology used to arrive at the estimates for burden, intervention use and funding for years up to 2008. These estimates for the global level are presented in Part I: Malaria Today and for four regions (Africa, The Americas, Asia-Pacific, and Middle East and Eurasia) in Part III: Regional Strategies. For a discussion of projected estimates of interventions and costs beyond 2008, please see Appendix 4.

Current Burden Estimates

Burden data estimates the number of malaria cases and malaria deaths. These variables provide a starting place to assess the morbidity and mortality of malaria across countries and regions.

Baseline burden estimate. In 2006, the RBM Partnership, led by the Monitoring and Evaluation Reference Group (MERG), developed a consensus estimate of global malaria deaths and cases by region to serve as the 2000 baseline for the RBM targets. This work was published in Jamison DT, Breman JG et al, editors. Disease Control Priorities in Developing Countries Conquering Malaria. Oxford University Press and the World Bank; 2006 in the chapter by Breman JG et al. on Conquering Malaria. The global number of malaria cases is estimated for 2002 and global deaths from malaria for 2000. The GMAP uses the Breman 2000 and 2002 baseline data on burden to report burden at a global level and at a regional level.

The specific range of 350 – 500 million cases per year was validated by work by Korenromp E in Malaria incidence estimates at country level for the year 2004 – Proposed estimates and draft report. Geneva, Roll Back Malaria, 2005 and is within the inter-quartile range reported by Breman. The 2000 estimate of 1 million deaths globally is closely related to the 804,000 deaths in Africa estimated by Rowe AK et al in The burden of malaria mortality among African children in the year 2000. International Journal of Epidemiology, 2006, 35:691-704.

2006 burden estimate from WHO World Malaria Report 2008. In September 2008, the World Health Organization released its latest World Malaria Report (WMR) 2008. The WMR 2008 contains information on burden, policies, coverage and funding for 109 malaria endemic countries as of 2006. In the report, WHO uses an updated and revised methodology to estimate the incidence of malaria outside the African Region. Annex 1 of WMR 2008 describes the methodology.

This new methodology results in fewer malaria cases than previously estimated in the Americas, Eastern Mediterranean, Europe, Southeast Asia and Western Pacific regions. The main reason for the difference is the use of a new estimation method, based on adjusting case reports. The lower figures derived by the new method have been approved by WHO regional and country offices, and they are consistent with the views of some other authors that have found previous estimates to be too high (e.g. in the Western Pacific Region).

WMR estimates of the numbers of cases and deaths in Africa are not significantly different from previous estimates. All recent, published estimates of malaria burden are surrounded by wide uncertainty intervals, and the intervals obtained in various studies overlap. Thus the 212 million cases estimated for the African Region in WMR 2008 are about the same as the 210 million and 230 million previously obtained in separate studies by Snow et al[3]Snow NW et al. The public health burden of Plasmodium falciparum malaria in Africa: deriving the numbers. Bethesda, Maryland, USA, Fogarty International Center / National Institutes of Health, 2003 (The Disease Control Priorities Project (DCPP) Working Paper Series No. 11). and Korenromp.[4]Korenromp E. Malaria incidence estimates at country level for the year 2004. Geneva, World Health Organization, 2005 (draft).

Click for source
Likewise the 801,000 deaths lie within the range 700,000 - 1.6 million published by Snow et al.[5]Snow NW et al. The public health burden of Plasmodium falciparum malaria in Africa: deriving the numbers. Bethesda, Maryland, USA, Fogarty International Center / National Institutes of Health, 2003 (The Disease Control Priorities Project (DCPP) Working Paper Series No. 11).

Methodology for updating burden estimates. Experts in this field agree that the methods for evaluating malaria burden and trends, and the underlying data, can be improved further. RBM partners, including WHO, are continuing to improve and align estimates of malaria burden worldwide. MERG has two teams tasked with updating and aligning future morbidity and mortality estimates for the RBM Partnership.

Estimates of current interventions

Reviewing the most recent data on number of interventions is essential to identify where countries are today (or as recently as possible) in providing interventions to their populations. It also will show the gaps that need to be filled to achieve universal coverage with all interventions. The methodology for estimating future intervention needs is covered in Appendix 4.

Scope of estimates. In the GMAP, global and regional interventions were calculated bottom-up based on data from 109 malaria-endemic countries for the major intervention types (LLINS / ITNs, IRS, diagnostics, treatment). Data reported was for the most recent year available (2006), although not all countries reported data for 2006.

Data sources. The primary data source was the WHO World Malaria Report 2008 (WMR) because the WMR includes both program data reported by countries and survey data from recent household surveys. In the GMAP, program data was used to estimate the number of interventions for two reasons. First, while household surveys are an effective way to assess local usage, the results are less readily aggregated and compared across entire countries and regions. Second, program data has the advantage that it covers all 4 major interventions whereas survey data mostly covers LLINS / ITNs and treatment interventions. When it existed, data from household surveys was reported in the GMAP as well to provide a more wholistic picture of trends in intervention utilization.

The WMR data was supplemented with data from the RBM Commodities Services database when available. The commodities data was compiled by the RBM Partnership. This data includes national procurement figures provided by pharmaceutical companies and international organisations. The procurement figures are considered a good proxy for national coverage figures even if they tend to overestimate coverage. This problem was considered minor as only a small number of coverage figures were derived using procurement figures (5 countries for LLINS / ITNs and 20 countries for treatment).

For countries where both the World Malaria Report and RBM data were not available, the plan assumed zero coverage for these countries. The data sources are summarized in Table A.1.

Table A.1: Availability of country data by intervention

Intervention Countries with WMRa program data Add. countries with RBMb commodities data Total number of countries with data
LLINs / ITNs 78 5 83
IRS 75 0 75
Diagnostics 71 0 71
Treatment 61 20 81

a) World Malaria Report 2008. Geneva, World Health Organization, 2008.
b) Roll Back Malaria Partnership

Adjustments were made to the WHO WMR data to calculate the number of interventions for the GMAP estimates:

The above adjustments explain 100% of differences between the coverage data used in the WMR and the GMAP. Figure A.1 provides an example of the differences between the WMR and GMAP estimates for the number of LLINs / ITNs distributed in Africa.

Figure A.1: Reconciliation of WMR and GMAP data for LLINs / ITNs in Africa

Source: World Malaria Report 2008. Geneva, World Health Organization, 2008.

Description of calculations for each intervention. The GMAP primarily states the level of interventions in terms of absolute numbers of interventions required because this variable is the most relevant for those making purchasing decisions.

LLINS / ITNs. The figures for LLINS / ITNs are calculated as follows:

IRS. The figures for IRS are calculated as follows:

Diagnostics. The figures for diagnostics are calculated as follows:

Anti-malarial treatment. The figures for anti-malarial treatments are calculated as follows:

Current Funding Estimates

This section presents the scope, data sources and hypothesis used to assess the current malaria funding (up to 2007) and estimated funding for 2008.

Scope of funding estimates. Estimates of current levels of funding for malaria are presented at the global level in Part I – Chapter 4: Funding for Malaria Today and at the regional level for the four regions of GMAP (Africa, The Americas, Asia-Pacific, and Middle East and Eurasia) in Part III: Regional Strategies.

Global Estimates. Part I – Chapter 4: Funding for Malaria Today presents figures aggregated at the global level for:

As there are significant differences in the amounts and timing between pledges and actual disbursements, figures in GMAP represent annual disbursements (as opposed to commitments) when they were available. This is intended to match the availability of funds as closely as possible to when intervention could be purchased or money used for program costs. When information was not available about disbursements, data on budgets or commitments was used.

Regional Estimates. Part III – Regional Strategies presents a regional allocation of current malaria resources. Figures presented in this chapter represent 2007 regional disbursements including national government spending from endemic countries and funding from major international donors (all listed above except USAID projects other than President’s Malaria Initiative (PMI) for which country or regional allocation was not publicly available). As private household spending was estimated at the global level only, this amount is excluded from figures presented in the regional chapters.

Figure A.2 illustrates the link between global figures presented in Part I: Malaria Today and regional figures presented in Part III: Regional Strategies of the plan.

Figure A.2: Reconciliation of global and regional funding data

Source: World Malaria Report 2008. Geneva, World Health Organization, 2008 (Government, UN Agencies, Bilaterals, EU), the Global Fund website, PMI operational plans, USAID website, World Bank Booster Program.

Data Sources. No single data source provided a comprehensive assessment of current funding so estimates were built from different sources. The summary below describes the data sources and the methodology for each of the major types of malaria funding: Malaria-endemic country spend, Private household spend, and Funding from international donors.

Malaria-endemic country spend (2007). Information on malaria endemic-country spend are data reported by each country to WHO and gathered in the WHO World Malaria Report 2008. The data represents total government malaria budget reported to WHO. 2007 data was used when available. As only a few countries reported 2007 information, data from previous years was used (mostly 2006 but also 2005 when 2006 was not available). When none of these figures where available, government malaria budgets reported in the Needs Assessments developed with the support from the RBM Harmonization Working Group were also used. The total amount might be underestimated as figures for only 71 countries were available. These 71 countries represent ~84% of global malaria deaths.

Private household spend (2007). Figures for private household spend are based on estimated size of private market for drugs ($130M) and insecticide-treated nets ($150M). Private drug spend assumes treatment volume of 10 million ACTs, 396 million monotherapies with fully-loaded cost of US$ 0.75 pediatric ACT, US$ 1.50 adult ACT, US$ 0.3 monotherapy. Private spend for insecticidal nets assumes US$ 107 million in net sales with distribution costs of 37.5% of sales.

Funding from international donors (2004-2007 and 2008 estimate). Funding from international donors was calculated for each of the major donors: the Global Fund, the President’s Malaria Initiative, the World Bank, bilaterals and other donors.

Spending on malaria Research and Development. Figures correspond to disbursements for malaria R&D. Funding from the Bill and Melinda Gates Foundation assumes that grants are evenly disbursed for the calendar year in which they are active. National Institutes of Health (NIH) funding is based on actual spend for 2003-2006 and budget projections for 2007-2008.[11]NIH data

Click for source
Other funding for R&D by the private sector companies, US Department of Defense, Wellcome Trust, and others is assumed to hold flat at US$ 165 million based on the Malaria R&D Alliance reported funding estimate for 2004.